IGC Provides Update on Phytocannabinoid IP Portfolio
03 November 2016 - 12:33AM
India Globalization Capital, Inc. (NYSE MKT:IGC) announces updates
for five patents related to method and treatment of pain, seizures
and eating disorders utilizing a combination of Phytocannabinoid
Cannabidiol (CBD) and other compounds.
Indication |
Provisional Filing |
PCT Filing |
Subsequent Activity |
Pain (Case 1) |
9/16/14 |
9/16/15 |
US National Case Filed – 6/15/16 |
Seizures (Case 2) |
6/15/15 |
6/14/16 |
US National Case Filed – 6/15/16 |
Seizures (Case 3) |
4/1/15 |
4/1/16 |
PCT Application Published- 10/6/16 |
Eating Disorders (Case 4) |
8/12/15 |
8/11/16 |
US and National Filing Anticipated 2/12/18 |
Seizures (Case 5) |
6/15/16 |
Anticipated- 6/15/17 |
US and National Filing Anticipated 12/15/18 |
Phytocannabinoids are chemical compounds that exert
a range of effects on the human body, including impacting the
immune response, gastrointestinal maintenance and motility, muscle
functioning, and nervous system response and functioning. We have
filed five provisional patents with the United States Patent and
Trademark Office (“USPTO”), in the combination therapy space, for
the indications of Pain, Medical Refractory Epilepsy and Cachexia
as part of our intellectual property strategy focused on the
phytocannabinoid based health care industry. The above table
summarizes the latest corporate activities and it should be noted
that there is no guarantee that filing a provisional or a
non-provisional patent application will result in a successful
registration with the USPTO.
As previously reported, approximately 50 million
people worldwide are affected by Epilepsy (Sanders, 2003).
Epilepsy is thought to be due to multiple factors that include
Sodium, Potassium, GABA (gamma amino butyric acid) and NMDA
(N-Methyl-d-aspartate). It is believed that to maximally
control Epilepsy, modulation of one or more of these receptors is
required and that mono therapy is adequate in up to 25% of
patients.
The pain market represents a significant component
of the healthcare system and The Journal of Pain in September 2012
reported that the annual estimated national cost of pain ranges
from $560 billion to $635 billion. Additionally, The American Pain
Society recommends that pain be made more visible and be
categorized as the fifth vital sign.
Cachexia is a condition that accompanies severe
illness such as cancer and results in the weakness and wasting away
of the body. In the U.S. it is estimated that a population of
approximately 1.3 million are experiencing Cachexia associated with
Cancer, Multiple Sclerosis, Parkinson’s disease, HIV/AIDS and other
progressive illnesses. Cancer induced Anorexia Cachexia is
responsible for about 20% of all cancer deaths.
Mr. Ram Mukunda, CEO of IGC commented, “We see a
significant opportunity in phytocannabinoid-based therapies and
these additional filings further strengthen our current IP
portfolio which encompasses the indications of Pain, Medical
Refractory Epilepsy and Cachexia.”
About IGC
In the United States, we develop
phytocannabinoid-based therapies. IGC has assembled a portfolio of
patent filings that encompasses the indications of Pain, Medical
Refractory Epilepsy and Cachexia using cannabinoids. We are
based in Bethesda, Maryland.
Our website: www.igcinc.us. Twitter @IGCIR
Facebook.com/IGCIR/
Contact:
Claudia Grimaldi 301-983-0998